Tuesday, June 21, 2016
- 12:30pm-2:00pm
-
Generation of dopaminergic neurons for studying Parkinson’s disease using patient blood cells
Parkinson's disease: Pathophysiology · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Generation of human induced pluripotent stem cells carrying a safety bet for cell-based therapy in Parkinson’s disease
Therapy in movement disorders: Gene and cell-based therapies · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Genetic analysis of CHCHD2 gene in Parkinson’s disease in a Taiwanese population
Parkinson's disease: Genetics · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Genetic analysis of eighty-seven multiple system atrophy patients
Genetics (NON-PD) · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Genetic Identification of early-onset parkinsonism among Norwegian patients
Parkinson's disease: Genetics · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Genetic risk factors of dementia and psychosis in Parkinson’s disease
Parkinson's disease: Genetics · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Genetic variation near the SNCA gene associates with Parkinson’s disease motor phenotype and progression
Parkinson's disease: Genetics · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Genome-wide bioinformatic analysis of Parkinson’s disease: A focus on neuronal health maintenance
Parkinson's disease: Genetics · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Parkinson's disease: Pathophysiology · Exhibit Hall located in Hall B, Level 2
- 12:30pm-2:00pm
-
Glucocerebrosidase activity in a cohort of PD patients
Parkinson's disease: Pathophysiology · Exhibit Hall located in Hall B, Level 2
- «Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 48
- Next Page»